Cencora (NYSE:COR) Issues FY 2025 Earnings Guidance

Cencora (NYSE:COR) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 14.800-15.100 for the period, compared to the consensus EPS estimate of 13.640. The company issued revenue guidance of $314.5 billion-$320.4 billion, compared to the consensus revenue estimate of $292.7 billion. Cencora also updated its FY25 guidance to $14.80-15.10 EPS.

Wall Street Analysts Forecast Growth

COR has been the subject of several recent analyst reports. Leerink Partners decreased their target price on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a report on Monday, October 7th. Barclays lifted their price objective on shares of Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday. Robert W. Baird raised their target price on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research report on Thursday. JPMorgan Chase & Co. upped their price target on Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research report on Wednesday, August 21st. Finally, UBS Group raised their price objective on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research report on Thursday. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Cencora currently has an average rating of “Moderate Buy” and a consensus price target of $271.20.

Cencora Stock Performance

Shares of COR opened at $248.42 on Friday. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93. Cencora has a 12 month low of $191.11 and a 12 month high of $251.00. The company’s fifty day moving average is $231.95 and its 200-day moving average is $230.84. The firm has a market cap of $48.95 billion, a price-to-earnings ratio of 33.08, a price-to-earnings-growth ratio of 1.49 and a beta of 0.44.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, November 6th. The company reported $3.34 earnings per share for the quarter, beating the consensus estimate of $3.21 by $0.13. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The company had revenue of $79.05 billion for the quarter, compared to analyst estimates of $77.68 billion. Equities analysts expect that Cencora will post 13.64 EPS for the current fiscal year.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, November 29th. Stockholders of record on Friday, November 15th will be given a $0.55 dividend. This is a positive change from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date is Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.89%. Cencora’s dividend payout ratio (DPR) is currently 29.29%.

Insiders Place Their Bets

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total value of $5,071,822.20. Following the sale, the chairman now owns 285,088 shares of the company’s stock, valued at $67,223,750.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 15.80% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.